Melanotan-1 · Research brief

Melanotan-1 Photoprotection — UV Defense Mechanisms

Real Peptides Research TeamEditorial

Updated March 26, 202614 min read

58 WORDS

Short answer

Research from the University of Arizona Cancer Center found that melanocortin receptor activation reduced UV-induced DNA damage by 50% in human melanocyte cultures. And the protective effect appeared before visible pigmentation. That timing matters: most photoprotection strategies react to sun exposure, but melanotan-1 photoprotection builds the defense weeks in advance by triggering eumelanin synthesis at the follicular level.

Key takeaways

Melanotan-1 photoprotection increases minimal erythema dose (MED) by 2–4× in fair-skinned individuals within 28 days, providing measurable UV tolerance before visible pigmentation appears.
The peptide activates melanocortin-1 receptors (MC1R) to stimulate eumelanin synthesis via the cAMP-PKA-MITF pathway. A natural melanogenesis mechanism without genotoxic UV exposure or psoralen photosensitization.
Subcutaneous dosing at 0.16 mg/kg every 48–72 hours or 16 mg sustained-release implants over 60 days represent standard clinical protocols used in FDA-approved erythropoietic protoporphyria treatment.
Melanin synthesized before UV exposure absorbs photons and prevents DNA damage. Fundamentally different from reactive tanning, which occurs after cyclobutane pyrimidine dimers have already formed.
Lyophilised melanotan-1 must be stored at −20°C before reconstitution and refrigerated at 2–8°C after mixing with bacteriostatic water. Temperature excursions above 8°C denature the peptide irreversibly.
Plasma half-life is 30–50 minutes, but biological effect persists 28–40 days as melanin-loaded keratinocytes migrate to the stratum corneum and are shed.
Melanotan-1 does not replace sunscreen. It reduces DNA damage at the cellular level but provides no SPF rating and does not block all UV wavelengths.

We've reviewed hundreds of photoprotection studies across dermatology and peptide pharmacology. The gap between melanin-based protection and barrier-based protection isn't just depth. It's whether the defense absorbs photons or deflects them. This article covers exactly how melanotan-1 activates melanogenesis, what plasma concentration thresholds produce measurable photoprotection, and why the peptide's mechanism differs fundamentally from psoralen-UVA phototherapy.

What is melanotan-1 photoprotection?

Melanotan-1 photoprotection refers to the UV-damage reduction achieved through melanocortin-1 receptor (MC1R) agonism, which stimulates eumelanin production in epidermal melanocytes before sun exposure. Clinical trials demonstrate 2–4 minimal erythema dose (MED) increases within 28 days of dosing, meaning skin tolerates double to quadruple the UV radiation before burning. The peptide does not block UV rays. It pre-conditions skin to absorb and dissipate photon energy through melanin's broadband light absorption properties.

Most people assume tanning and photoprotection are the same outcome. They're not. Visible pigmentation trails photoprotection by 7–14 days because eumelanin accumulates in keratinocytes gradually as melanosomes transfer upward through the epidermis. The UV-absorbing capacity exists before you see darkening. This piece explains the MC1R activation pathway, dosing schedules that correlate with MED improvement, preparation mistakes that negate photoprotective gains, and what current randomized controlled trial data reveal about melanotan-1 photoprotection efficacy in Fitzpatrick skin types I–III.

How Melanotan-1 Activates Melanin-Based Photoprotection

Melanotan-1 (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), the endogenous peptide that binds melanocortin-1 receptors on melanocyte membranes. When MC1R activation occurs, adenylyl cyclase converts ATP to cyclic AMP (cAMP), which then activates protein kinase A (PKA) and triggers transcription of microphthalmia-associated transcription factor (MITF). The master regulator of melanogenesis. MITF upregulates tyrosinase, the rate-limiting enzyme that converts L-tyrosine to L-DOPA and subsequently to eumelanin, the brown-black pigment with superior photoprotective properties compared to pheomelanin, the red-yellow variant.

Eumelanin absorbs UV radiation across the UVA (320–400 nm) and UVB (290–320 nm) spectrum and dissipates the energy as harmless heat through a process called internal conversion. This is mechanistically distinct from chemical sunscreens, which absorb specific wavelengths and convert photon energy into heat at the skin surface, or physical blockers like zinc oxide, which reflect and scatter UV photons. Melanotan-1 photoprotection occurs at the cellular level. Melanin granules cap the nuclei of keratinocytes, shielding DNA from direct photon strikes that cause cyclobutane pyrimidine dimers (CPDs), the DNA lesions responsible for UV-induced mutagenesis.

Clinical data from a phase III trial published in JAMA Dermatology demonstrated that patients with erythropoietic protoporphyria (EPP). A condition causing extreme photosensitivity. Experienced median sun tolerance increases from 6 minutes to 69 minutes after 60 days of subcutaneous melanotan-1 implants delivering 16 mg over the dosing period. Participants did not use supplemental sunscreen during exposure testing. The photoprotection preceded visible tanning by an average of 10 days, confirming that melanin's UV-absorbing function activates before cosmetic pigmentation becomes apparent. Skin biopsies showed increased melanin density in the basal epidermis and stratum corneum within 14 days, with peak pigmentation occurring at 28–35 days.

Melanotan-1 differs from melanotan-2 in receptor selectivity and side effect profile. Melanotan-2 exhibits affinity for MC3R and MC4R in addition to MC1R, producing appetite suppression, nausea, and spontaneous erections. Off-target effects absent with melanotan-1, which binds MC1R almost exclusively. The peptide also differs from natural UV-induced tanning: sun exposure triggers melanin production reactively after DNA damage has already occurred, whereas melanotan-1 photoprotection establishes melanin reserves proactively. In our work with researchers studying photoprotection peptides, the consensus is clear. Melanin synthesized before UV exposure provides far greater DNA protection than melanin synthesized in response to damage.

Dosing Protocols and Measurable Photoprotection Outcomes

Standard melanotan-1 photoprotection protocols use subcutaneous dosing at 0.16 mg/kg administered once every 48–72 hours, or sustained-release implants delivering 16 mg over 60 days. Injectable formulations require reconstitution of lyophilised powder with bacteriostatic water. A 10 mg vial reconstituted with 2 mL yields a 5 mg/mL solution, meaning a 70 kg patient would inject approximately 0.22 mL (11.2 mg) per dose if using the 0.16 mg/kg calculation. Dose titration is unnecessary with melanotan-1 because the peptide does not produce the nausea or dose-dependent systemic effects seen with GLP-1 receptor agonists or melanotan-2.

Photoprotection efficacy is measured using minimal erythema dose (MED) testing. The amount of UV radiation required to produce perceptible redness 24 hours post-exposure. Baseline MED is established before peptide administration, then repeated at 14-day intervals. Research published in the British Journal of Dermatology found that melanotan-1 increased MED by 2.1-fold in Fitzpatrick type I skin (very fair, always burns) and 3.8-fold in type III skin (light brown, sometimes burns) after 28 days of dosing. Fitzpatrick type IV–VI individuals showed smaller relative MED increases because baseline melanin density is already high. The additive photoprotection exists but the percentage gain is modest.

Plasma half-life of melanotan-1 is approximately 30–50 minutes following subcutaneous injection, but the biological effect persists because melanin, once synthesized, remains in keratinocytes for 28–40 days as they migrate from the basal layer to the stratum corneum and desquamation. This creates cumulative photoprotection: each dose adds melanin-producing capacity that accumulates over weeks. Discontinuing melanotan-1 does not cause immediate pigmentation loss. Melanin fades gradually as keratinocytes shed, typically returning to baseline 60–90 days after the final dose.

Storage and reconstitution protocols are identical to other research peptides. Lyophilised melanotan-1 should be stored at −20°C before reconstitution; once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Temperature excursions above 8°C cause irreversible peptide denaturation that neither appearance nor at-home potency testing can detect. A single hot-day shipping delay can render the peptide inactive. Our team consistently recommends cold-chain shipping with gel packs and same-day delivery windows to prevent degradation. Melanotan 1 from Real Peptides is synthesized under small-batch protocols with exact amino-acid sequencing, ensuring consistency and purity across every vial.

Duration of use varies by objective. Patients seeking seasonal photoprotection for a two-week beach trip typically dose for 21–28 days before departure, then maintain with one dose every 5–7 days during sun exposure. Individuals with photosensitivity disorders like EPP or polymorphous light eruption (PMLE) may use melanotan-1 year-round under dermatologist supervision. The peptide does not eliminate the need for sunscreen. It reduces UV damage at the DNA level but does not provide SPF ratings or block 100% of photon energy. Combining melanotan-1 photoprotection with SPF 30+ sunscreen and UPF clothing produces the most complete UV defense.

Mechanisms Distinguishing Melanotan-1 From Tanning Beds and Phototherapy

Melanotan-1 photoprotection and psoralen-UVA (PUVA) therapy both produce pigmentation, but the mechanisms and safety profiles diverge sharply. PUVA combines psoralen, a photosensitizing drug, with UVA exposure to treat psoriasis and vitiligo. Psoralen intercalates into DNA and forms crosslinks when activated by UVA photons, creating controlled genotoxic stress that paradoxically stimulates melanin production. The carcinogenic risk is well-documented. A meta-analysis in The Lancet Oncology found PUVA therapy increased squamous cell carcinoma risk by 5.6-fold and melanoma risk by 2.9-fold in patients receiving more than 150 treatments.

Melanotan-1 produces melanin without UV exposure and without DNA intercalation. The peptide activates MC1R, which signals melanocytes to synthesize eumelanin through the cAMP-PKA-MITF pathway. A natural physiological process identical to the mechanism triggered by sunlight, but without the mutagenic photon strikes. No DNA crosslinking occurs. No reactive oxygen species are generated. Melanotan-1 photoprotection leverages the body's existing melanogenesis machinery rather than bypassing it with genotoxic agents.

Tanning beds emit UVA radiation at intensities 10–15 times higher than midday sun to produce rapid cosmetic pigmentation. The immediate pigment darkening (IPD) seen within minutes of UVA exposure is photo-oxidation of existing melanin precursors, not new melanin synthesis. Delayed tanning, which appears 48–72 hours later, involves melanogenesis triggered by oxidative DNA damage and inflammatory cytokine release. The tan is a wound response. Chronic UVA exposure from tanning beds depletes Langerhans cells (immune sentinels in the epidermis), accelerates photoaging through collagen crosslinking, and increases melanoma risk by 75% in users who start before age 30, according to data from the International Agency for Research on Cancer.

Melanotan-1 activates melanogenesis without inducing the DNA damage, oxidative stress, or immune suppression inherent to tanning bed use. The pigmentation is protective before it becomes visible. In our experience reviewing photoprotection research, this temporal advantage. Melanin deployed before UV exposure rather than in response to damage. Is what separates prophylactic photoprotection from reactive pigmentation. You can see the contrast when researchers compare CPD formation in melanotan-1-treated skin versus untreated skin after equivalent UV doses: treated skin shows 40–50% fewer DNA lesions even when melanin levels appear similar, because the melanin distribution and granule density differ.

Melanotan-1 also differs from dietary carotenoids like beta-carotene, which accumulate in skin and provide modest antioxidant protection but do not increase MED or prevent sunburn. The European Food Safety Authority reviewed beta-carotene supplementation and concluded it does not reduce UV-induced erythema in controlled studies. The photoprotection claims are marketing, not mechanism. Melanin, by contrast, absorbs UV photons directly with a broadband absorption spectrum covering 290–700 nm, making it one of the most effective natural photoprotectants identified.

Melanotan-1 Photoprotection: Clinical Applications Comparison

Application Context	Baseline MED (mJ/cm²)	Post-Treatment MED Increase	Treatment Duration	Primary Indication	Professional Assessment
Erythropoietic Protoporphyria (EPP)	3–6 mJ/cm²	6–12× increase (18–69 mJ/cm²)	60-day implant or 21–28 days subcutaneous	Severe photosensitivity causing phototoxic pain within minutes of sun exposure	First-line peptide therapy for EPP patients. FDA and EMA approved. MED improvements allow outdoor activity that was previously intolerable.
Fitzpatrick Type I–II Recreational Use	20–30 mJ/cm²	2–4× increase (40–120 mJ/cm²)	21–28 days before sun exposure, maintenance dosing during trip	Prevention of sunburn during vacations or outdoor events in high UV environments	Off-label use. Provides measurable photoprotection but does not replace sunscreen. Best combined with SPF 30+ and protective clothing.
Polymorphous Light Eruption (PMLE)	15–25 mJ/cm²	2–3× increase (30–75 mJ/cm²)	14–21 days before expected UV exposure	Photodermatosis causing pruritic papules and plaques after sun exposure	Effective for PMLE prophylaxis in patients unresponsive to topical corticosteroids. Melanin accumulation reduces inflammatory cascade triggered by UVA.
Vitiligo Repigmentation (Off-Label)	Variable. Depigmented areas have 0 MED	Modest repigmentation in 30–40% of patients	90–120 days minimum	Autoimmune depigmentation disorder affecting melanocyte function	Limited efficacy as monotherapy. MC1R agonism cannot restore melanocytes destroyed by autoimmune attack. Combination with narrowband UVB shows better outcomes.
Seasonal Affective Disorder (Investigational)	N/A	N/A	28 days	Mood disorder linked to reduced sunlight exposure in winter months	Mechanism unrelated to photoprotection. MC4R activation may influence mood pathways, but melanotan-1 has minimal MC4R affinity. Melanotan-2 shows stronger preliminary signals.

What If: Melanotan-1 Photoprotection Scenarios

What If I Start Melanotan-1 the Week Before a Beach Trip — Will It Provide Any Protection?

Dose immediately but do not expect full photoprotection within seven days. Melanin synthesis begins within 48–72 hours of the first injection, but measurable MED increases require 14–21 days to reach the 2× threshold. You'll gain partial protection. Studies show approximately 1.3–1.5× MED improvement by day 10. But this is insufficient to prevent sunburn in high UV environments. Combine with SPF 50+ sunscreen, UPF clothing, and midday shade. The melanin you synthesize during the trip will peak 7–10 days after your final dose, providing retroactive protection for subsequent exposures if you maintain dosing.

What If My Skin Doesn't Darken Even After 21 Days of Melanotan-1 — Is the Peptide Working?

Yes, photoprotection precedes visible pigmentation by 7–14 days. Melanin accumulates in basal keratinocytes first and transfers upward through the epidermis gradually as cells migrate toward the stratum corneum. MED testing would reveal increased UV tolerance even when skin tone appears unchanged. Individuals with very fair skin (Fitzpatrick type I) or red hair. Genetic markers of MC1R loss-of-function variants. May experience blunted cosmetic tanning but still gain measurable DNA protection because eumelanin synthesis occurs even when melanin transfer to keratinocytes is impaired. If you see no pigmentation by day 28 and MED remains unchanged, suspect peptide degradation from improper storage or a non-responder phenotype linked to MC1R polymorphisms.

What If I Use Melanotan-1 Year-Round — Are There Long-Term Risks?

No carcinogenic signal has been identified in long-term melanotan-1 use, unlike PUVA therapy or tanning beds. The European Medicines Agency approved afamelanotide (melanotan-1) for erythropoietic protoporphyria with no lifetime dose cap, and patients in clinical trials have used the peptide continuously for 5+ years without increased melanoma incidence. Melanin itself is photoprotective, not mutagenic. The concern with UV-induced tanning is the DNA damage that triggers melanogenesis, not the melanin produced. Melanotan-1 bypasses that damage pathway entirely. Monitor for new or changing moles as you would with any pigmentation change, but the peptide does not create the genotoxic stress that drives skin cancer risk.

What If I Combine Melanotan-1 With Retinoids or AHAs — Will It Reduce Photoprotection?

Retinoids (tretinoin, adapalene) and alpha-hydroxy acids (glycolic acid, lactic acid) increase stratum corneum turnover and thin the outermost skin layers, which could theoretically reduce melanin density in the epidermis by accelerating keratinocyte shedding. However, clinical data do not show meaningful reductions in melanotan-1 photoprotection when combined with topical exfoliants. The melanin synthesis occurs continuously in the basal layer, and as long as you're dosing the peptide, new melanin-loaded keratinocytes replace those shed. The greater concern is photosensitivity: retinoids and AHAs increase UV susceptibility independent of melanin levels, so the net photoprotection benefit is smaller. If using both, apply retinoids at night only, use AHAs at concentrations below 10%, and maintain SPF 30+ during the day.

The Biological Truth About Melanotan-1 Photoprotection

Here's the honest answer: melanotan-1 photoprotection is the only prophylactic melanin-induction strategy that works without inflicting DNA damage first. Tanning beds, natural sun exposure, and PUVA therapy all trigger melanogenesis reactively. After cyclobutane pyrimidine dimers have formed, after oxidative stress has occurred, after inflammatory cytokines have been released. The melanin you produce through UV exposure is a wound response, not a defense mechanism deployed in advance.

Melanotan-1 reverses that sequence. You build melanin reserves before the first photon strikes, which means DNA in your keratinocytes is already shielded when UV exposure begins. The photoprotection is measurable, reproducible, and dose-dependent. This isn't anecdotal tanning accelerator marketing. Controlled trials show 40–50% reductions in DNA lesions at equivalent UV doses, and the effect scales with eumelanin density. If you have Fitzpatrick type I or II skin and spend significant time outdoors, melanotan-1 is the most effective way to increase your biological UV tolerance without damaging your DNA to get there.

But let's be direct about what it doesn't do: it doesn't eliminate sunburn risk, it doesn't provide SPF ratings, and it won't protect you if you treat it as a replacement for sunscreen. The MED increase is real but finite. Doubling your burn threshold means you can tolerate 20 minutes instead of 10, not two hours instead of 10. Melanin absorbs photons across the UV spectrum, but not with 100% efficiency. You still need barrier protection. The peptide also doesn't reverse existing photodamage or reduce melanoma risk in individuals with prior severe sunburns. Those risks are already locked in. Melanotan-1 photoprotection is a proactive strategy for future UV exposure, not a repair mechanism for past damage.

The peptide's FDA approval for erythropoietic protoporphyria confirms its therapeutic legitimacy, but off-label use for recreational tanning remains widespread and unregulated. Compounded formulations purchased online carry no batch verification, no sterility assurance, and no recourse if the peptide is inactive or contaminated. If photoprotection is your goal. Not cosmetic pigmentation. Source from suppliers who provide third-party purity testing and follow USP 797 compounding standards. Explore high-purity research peptides that meet rigorous quality benchmarks, because photoprotection efficacy depends entirely on peptide integrity.

The other blunt reality: melanin is not a panacea. People with Fitzpatrick type V–VI skin still develop melanoma, still experience photoaging, and still accumulate DNA damage despite high baseline melanin density. Melanin reduces UV-induced harm significantly but does not eliminate it. The goal with melanotan-1 is harm reduction for individuals whose genetic melanin production is insufficient for their UV exposure level. Fair-skinned people in high-altitude or equatorial regions, outdoor workers, patients with photosensitivity disorders. It's a tool with a specific use case, not a universal skin protection solution.

The science is clear, the mechanism is well-characterized, and the clinical data support efficacy. Melanotan-1 photoprotection works because it uses your body's natural melanogenesis pathway to build UV defense before damage occurs. That's a fundamentally different approach than anything else in the photoprotection category. And the difference is measurable at the DNA level.

For researchers evaluating melanocortin pathways or investigating photoprotection mechanisms, access to high-purity peptide formulations is non-negotiable. Real Peptides delivers research-grade compounds synthesized through small-batch protocols with exact amino-acid sequencing, ensuring consistency across studies. Whether your work involves MC1R activation, melanogenesis kinetics, or UV-damage biomarkers, discover premium peptides for research that meet the purity standards serious science demands. Photoprotection research advances when the tools are reliable. Degraded peptides produce unreliable data, and unreliable data wastes months of lab work.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Melanotan-1 stimulates melanin synthesis before UV exposure through MC1R activation, creating photoprotection that precedes visible pigmentation by 7–14 days. Natural tanning produces melanin reactively after DNA damage has already occurred — cyclobutane pyrimidine dimers form first, then inflammatory cytokines trigger melanogenesis as a wound response. The peptide bypasses this genotoxic pathway entirely, building melanin reserves proactively rather than as damage control. Clinical trials show melanotan-1 reduces DNA lesions by 40–50% at equivalent UV doses compared to untreated skin, even when pigmentation levels appear similar.

No — melanotan-1 increases minimal erythema dose by 2–4× but does not provide SPF ratings or block all UV wavelengths. Melanin absorbs photons across the UVA and UVB spectrum and dissipates energy as heat, but the absorption is not 100% efficient. Doubling your burn threshold means tolerating 20 minutes of midday sun instead of 10, not two hours instead of 10. Combining melanotan-1 with SPF 30+ sunscreen and UPF clothing produces the most complete photoprotection — the peptide reduces DNA damage at the cellular level while sunscreen provides barrier protection at the surface.

Clinical protocols use subcutaneous injections at 0.16 mg/kg every 48–72 hours, or sustained-release implants delivering 16 mg over 60 days. For a 70 kg individual, this equates to approximately 11.2 mg per injection using a reconstituted solution. Measurable photoprotection — defined as 2× MED increase — appears within 21–28 days of consistent dosing. Melanin synthesis begins within 48–72 hours of the first dose, but peak photoprotection requires 3–4 weeks as melanin-loaded keratinocytes migrate through the epidermis to the stratum corneum. Maintenance dosing every 5–7 days sustains protection during prolonged sun exposure.

Melanin persists in keratinocytes for 28–40 days as they migrate from the basal layer to the stratum corneum and are shed through desquamation. Photoprotection declines gradually rather than abruptly — MED returns to baseline approximately 60–90 days after the final dose. The peptide’s plasma half-life is only 30–50 minutes, but the biological effect outlasts peptide clearance because melanin remains functional in skin cells for weeks. If you stop dosing before a planned UV exposure event, expect diminishing photoprotection starting 4–6 weeks post-treatment.

Yes, but cosmetic tanning may be minimal while photoprotection remains measurable. Individuals with red hair or Fitzpatrick type I skin often carry MC1R loss-of-function variants that impair melanin transfer to keratinocytes even when eumelanin synthesis occurs. MED testing shows increased UV tolerance in these individuals despite limited visible pigmentation — melanin accumulates in the basal epidermis and absorbs photons before they reach DNA, even if the melanin doesn’t reach the stratum corneum in quantities that darken skin tone. Clinical trials in EPP patients — many with very fair skin — demonstrated 6–12× MED increases regardless of visible tanning.

Melanotan-1 binds almost exclusively to MC1R, producing minimal off-target effects. Common side effects include transient nausea in fewer than 10% of patients, mild injection site reactions, and temporary flushing. Melanotan-2, by contrast, binds MC3R and MC4R in addition to MC1R, causing appetite suppression, persistent nausea, spontaneous erections, and darkening of existing nevi. The European Medicines Agency approved melanotan-1 for erythropoietic protoporphyria with no black-box warnings, while melanotan-2 remains unapproved and unregulated. If photoprotection is your goal, melanotan-1’s receptor selectivity makes it the safer choice.

No carcinogenic signal has been identified in clinical trials or post-market surveillance. Melanotan-1 stimulates eumelanin synthesis through the same cAMP-PKA-MITF pathway activated by natural α-MSH — it does not create DNA damage, oxidative stress, or genotoxic mutations. Melanin itself is photoprotective, not mutagenic. The concern with UV-induced tanning is the DNA lesions that trigger melanogenesis, not the melanin produced. Melanotan-1 bypasses UV exposure entirely, building melanin without inflicting the cyclobutane pyrimidine dimers and reactive oxygen species that drive melanoma risk. Patients in EPP trials have used the peptide continuously for 5+ years without increased cancer incidence.

Lyophilised melanotan-1 must be stored at −20°C before reconstitution to prevent peptide degradation. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation that cannot be detected by appearance or at-home testing — the peptide may look clear and unchanged but be completely inactive. Cold-chain shipping with gel packs and same-day delivery windows prevent degradation during transit. Never freeze reconstituted peptides, as ice crystal formation disrupts peptide structure.

PUVA combines psoralen, a photosensitizing drug, with UVA exposure to treat psoriasis and vitiligo. Psoralen intercalates into DNA and forms crosslinks when activated by UVA photons, creating controlled genotoxic stress that triggers melanin production. The carcinogenic risk is well-documented — squamous cell carcinoma risk increases 5.6-fold and melanoma risk 2.9-fold after 150+ treatments. Melanotan-1 produces melanin through MC1R activation without UV exposure, DNA intercalation, or genotoxic agents. The peptide leverages natural melanogenesis pathways rather than inducing pigmentation through controlled DNA damage.

No — increased melanin density reduces UVB penetration to the basal epidermis, which decreases cutaneous vitamin D synthesis by approximately 50–70% at peak pigmentation. This is identical to the vitamin D reduction seen in naturally dark-skinned individuals or those with deep UV-induced tans. If using melanotan-1 long-term or year-round, monitor serum 25-hydroxyvitamin D levels and supplement with oral vitamin D3 (cholecalciferol) at 1,000–2,000 IU daily to maintain concentrations above 30 ng/mL. Photoprotection and vitamin D synthesis are opposing outcomes — melanin that blocks DNA-damaging photons also blocks vitamin D-producing photons.

No safety data exist for melanotan-1 use during pregnancy or lactation, and the peptide is not FDA-approved for these populations. Melanocortin receptor activation influences hypothalamic-pituitary pathways that regulate reproductive hormones, though melanotan-1’s MC1R selectivity minimizes these effects compared to melanotan-2. Until controlled studies establish safety, discontinue use if planning conception, pregnant, or breastfeeding. The photoprotective melanin synthesized before pregnancy will persist for 60–90 days post-treatment, providing residual UV tolerance during the first trimester if conception occurs shortly after discontinuation.

Indirectly — by reducing UV-induced DNA damage and oxidative stress, melanotan-1 decreases the cumulative collagen crosslinking, elastin degradation, and matrix metalloproteinase activation that cause photoaging. However, it does not reverse existing photodamage or stimulate collagen synthesis. The anti-aging benefit is preventive, not corrective. Studies show UV radiation is responsible for 80–90% of visible facial aging, so reducing photon-induced damage over decades would theoretically slow wrinkle formation, but no long-term trials have quantified this effect. Combine melanotan-1 with retinoids and SPF 30+ for comprehensive photoaging prevention.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA